ResHealth 2017
active
clinicaltrials


  1. An Audit of Hospital Admissions for Acute Exacerbations of Chronic Obstructive Pulmonary Disease AECOPD in Australia: Do we follow the guidelines? 2012 – 2015

  2. A prospective, randomised, placebo-controlled, double-blind, cross-over study of the efficacy of sustained-release morphine in the subjective sensation of dyspnoea due to maximally treated primary pulmonary hypertension in opioid naive participants. 2009 -

  3. A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial) – Amarin Pharma Inc. Protocol No: AMR-01-01-0019 . 2013 –

  4. Australian Xolair Register for Severe Asthma.  2013 –

  5. Phase 1 single centre, randomized, controlled, double-blind study to compare the safety and effectiveness of Hepatitis B vaccines in individuals with renal impairment, diabetes mellitus or age greater than 40 years. LOW RESPONDER HBV VACCINE STUDY (HBV002). 2013 –

  6. A multinational, multicenter study to assess the effects of oral sildenafil on mortality in adults with pulmonary arterial hypertension (PAH). Clinical Study No. A1481324. Pfizer. 2015 –

  7. A 52-week, double blind, randomised, multi-centre, parallel-group, Phase II study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort® (budesonide/formoterol) Turbuhaler® 160/4.5 µg ‘as needed’ compared with terbutaline Turbuhaler® 0.4 mg ‘as needed’ with Pulmicort® (budesonide) Turbuhaler® 200 µg twice daily plus terbutaline Turbuhaler® 0.4mg ‘as needed.’ Protocol Number: D589SC00001; AstraZeneca, 2015 –



    8.      A randomised double-blind, double-dummy parallel group study to compare the efficacy and safety of fluticasone propionate / formoterol fumarate (flutiform®) 500/20 µg BID and 250/10 µg BID versus salmeterol / fluticasone (Seretide®) 50/500 µg BID in subjects with chronic obstructive pulmonary disease (COPD). Protocol Number: FLT3510; Mundipharma, 2015 –

    9.      A Multicentre, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA) Protocol Number: D3250C00021; AstraZeneca, 2015 –

    10.  A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of switching from salmeterol/fluticasone to QVA149 (indacaterol maleate/glycopyrronium bromide) in symptomatic COPD patients. Protocol: CQVA149A3405; Novartis, 2015 –

    11.  A randomised, controlled, blinded phase 1 study to evaluate the immunogenicity and safety of a pandemic avian H5 influenza vaccine in adults (FLU003). 2015

    12.  A randomised, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo, administered for 14 days after the onset of symptoms of an upper respiratory tract infection for the prevention of severe exacerbations (INEXAS study). Protocol Number: D6230C00001; AstraZeneca, 2015 –

    13.  A multi-center, randomized, double-blind, placebo controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in asthma patients not adequately controlled by medium- or high-dose ICS plus LABA with or without OCS. Clinical Trial Protocol: CQGE031B2204; Novartis, 2015 –

    14.  A 52-week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosoniphils. Protocol Number: C38072-AS-30027; Teva Branded Pharmaceutical Products R&D, Inc., 2015 -

     

Please e-mail the inquiries to info@arasmi.org


affiliated with
follow us
©Copyright 2017. Arasmi.org
Email: info@arasmi.org

Powered by Digital Wave Media